Sugi Predict

Sugi Predict / Compounds / SCHEMBL372006

SCHEMBL372006

SCHEMBL372006

COc1cc2c(Oc3ccc(NC(=O)[C@@]4(C(=O)Nc5ccc(F)cc5)[C@H](C)[C@@H]4C)cc3F)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 18/20 0.73
▸ KIT P10721 7/20 0.73
▸ FLT3 P36888 7/20 0.73
▸ KDR P35968 6/20 0.73
▸ EGFR P00533 5/20 0.73
▸ PDGFRA P16234 5/20 0.73
▸ PDGFRB P09619 4/20 0.73
▸ AXL P30530 4/20 0.73
▸ MST1R Q04912 4/20 0.73
▸ ALK Q9UM73 3/20 0.73
▸ FLT4 P35916 2/20 0.73
▸ PLK4 O00444 2/20 0.73
▸ AURKA O14965 2/20 0.73
▸ RIPK2 O43353 2/20 0.73
▸ STK10 O94804 2/20 0.73
▸ MAP4K4 O95819 2/20 0.73
▸ FYN P06241 2/20 0.73
▸ YES1 P07947 2/20 0.73
▸ LYN P07948 2/20 0.73
▸ SRC P12931 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693457 1.00 MET (0.73) METKITFLT3KDREGFR
SCHEMBL372005 1.00 MET (0.73) METKITFLT3KDREGFR
SCHEMBL12443865 0.94 MET (0.73) METKITFLT3KDREGFR
SCHEMBL15580161 0.94 MET (0.73) METKITFLT3KDREGFR
SCHEMBL4405592 0.93 MET (0.85) METKITFLT3KDREGFR
SCHEMBL29693456 0.93 MET (0.85) METKITFLT3KDREGFR
SCHEMBL371942 0.93 MET (0.85) METKITFLT3KDREGFR
SCHEMBL19373139 0.93 MET (0.85) METKITFLT3KDREGFR
SCHEMBL29693469 0.93 MET (0.85) METKITFLT3KDREGFR
SCHEMBL372156 0.93 MET (0.85) METKITFLT3KDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885KIT 4/4885FLT3 7/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885KIT 5/4885FLT3 7/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KIT 4/4885FLT3 7/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KIT 4/4885FLT3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.